Global Hearts is the flagship initiative of the World Health Organization to reduce the burden of cardiovascular diseases, the leading cause of death and disability worldwide. HEARTS in the Americas Initiative is the regional adaptation that envisions HEARTS as the model for cardiovascular disease risk management, including hypertension and diabetes, in primary health care in the Americas by 2025. This initiative is entering its sixth year of implementation and now includes 22 countries and 1 380 primary health care centers. The objectives of this report are three-fold. First, it describes the emergence and the main elements of HEARTS in the Americas. Secondly, it summarizes the main innovations developed to catalyze and sustain implementation of the initiative. These innovations include: a) introduction of hypertension control drivers; b) development of a comprehensive and practical clinical pathway; c) development of a strategy to improve the accuracy of blood pressure measurement; d) creation of a monitoring and evaluation platform; and e) development of a standardized set of training and education resources. Thirdly, this report discusses future priorities of the initiative. The goal of implementing these innovative and pragmatic solutions is to create a more effective health system and shift the focus of cardiovascular and hypertension programs from the highly specialized care level to primary health care. In addition, HEARTS in the Americas can serve as a model for more comprehensive, effective, and sustainable noncommunicable disease prevention and treatment practices.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578652 | PMC |
http://dx.doi.org/10.26633/RPSP.2022.197 | DOI Listing |
Interdiscip Cardiovasc Thorac Surg
January 2025
Cardiac Surgery Department, Sanatorio Italiano, Asunción, Paraguay.
Coronary artery bypass graft surgery (CABG) remains the gold standard in the treatment of complex coronary artery disease (CAD). Saphenous vein grafts (SVG) are commonly used for the non-left anterior descending artery (LAD). However, SVG failure rates in CABG surgery have been reported to be as high as 30% at 1 year and ∼50% at 10 years.
View Article and Find Full Text PDFJACC Heart Fail
January 2025
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Background: Left ventricular (LV) dilatation and extensive scar portend a poor prognosis in heart failure (HF). The Revivent TC system (BioVentrix Inc) is used either during a hybrid transcatheter-surgical or a surgical-only procedure to exclude transmural scar and reduce LV dimensions.
Objectives: The purpose of this study was to examine the safety and efficacy of the Revivent TC® anchor system in patients with HF.
Eur J Prev Cardiol
January 2025
Saint Luke's Mid America Heart Institute, University of Missouri 4321 Washington Street, Suite 2400, Kansas City, MO 64111, USA.
J Clin Sleep Med
January 2025
Fundación Neumológica Colombiana, Bogotá, Colombia.
Study Objectives: REM-associated OSA (REM OSA) has a prevalence of 17-74% of all OSA cases. At high altitude and in Latin America, there are no data on REM OSA and its relationship to daytime sleepiness and comorbidities. This study aimed to determine the prevalence of REM OSA and the differences in clinical and polysomnographic characteristics between OSA and REM OSA in a population living at 2640 m.
View Article and Find Full Text PDFBMC Cardiovasc Disord
January 2025
Department of Cardiology, Peking University International Hospital, Life Park Road No.1, Life Science Park of Zhongguancun, Chang Ping District, Beijing, 102206, China.
Background: The transcatheter edge-to-edge repair (TEER) technique, facilitated by the MitraClip device, is a minimally invasive intervention designed for high-risk patients with mitral regurgitation (MR). This study conducts a retrospective analysis of death events associated with MitraClip implantation over a ten-year decade, utilizing data from the FDA's Manufacturer and User Facility Device Experience (MAUDE) database to evaluate trends in safety outcomes.
Methods: A comprehensive search of the publicly accessible MAUDE database was conducted to retrieve reports of deaths and injuries related to MitraClip implantation from October 2013 to September 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!